Program(s) for Tauopathies

About AviadoBio

AviadoBio is a private, clinical-stage biotech pioneering gene therapies for neurodegenerative diseases, with its lead program AVB-101 in Phase 1/2 trials for frontotemporal dementia (FTD-GRN). The company's strategy is built on a deep understanding of neuroanatomy and a suite of proprietary platforms, including the vMiX™ RNA silencing platform, designed to overcome the critical delivery challenges in treating neurological disorders. Founded on research from King's College London and the UK Dementia Research Institute, AviadoBio is backed by a strong syndicate of life science investors and is led by an experienced team, including CEO Lisa Deschamps. The company is pre-revenue and is advancing a pipeline that also targets retinitis pigmentosa, Alzheimer's/tauopathies, and ALS.

Therapeutic Areas

Other Alzheimer's Disease and other Tauopathies Drugs